Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights

(2019) Ammad Ahmad Farooqi et al.   SEMINARS IN CANCER BIOLOGY

The PHLPP2 phosphatase is a druggable driver of prostate cancer progression

(2019) Dawid G. Nowak et al.   JOURNAL OF CELL BIOLOGY

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis

(2019) Yen-Chun Liu et al.   MODERN PATHOLOGY

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

(2018) Giovanni Blandino et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion

(2018) Ramona Schulz-Heddergott et al.   CANCER CELL

Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis

(2018) Li Sun et al.   Cell Death & Disease

Molecular and histological study on the effects of electrolytic electroporation on the liver

(2018) Yanpeng Lv et al.   BIOELECTROCHEMISTRY

Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression

(2017) Xuetian Yue et al.   GENES & DEVELOPMENT

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

(2017) Kanaga Sabapathy et al.   Nature Reviews Clinical Oncology

Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1

(2017) Noriaki Tanaka et al.   ONCOGENE

Recent Insights into the Molecular Mechanisms Underlying Pyroptosis and Gasdermin Family Functions

(2017) Robin A. Aglietti et al.   TRENDS IN IMMUNOLOGY

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin

(2017) Armin Wiegering et al.   NEOPLASIA

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy

(2016) Chao He et al.   CHEMOTHERAPY

Global patterns and trends in colorectal cancer incidence and mortality

(2016) Melina Arnold et al.   GUT

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

(2016) Dawid Walerych et al.   NATURE CELL BIOLOGY

From tumour heterogeneity to advances in precision treatment of colorectal cancer

(2016) Cornelis J. A. Punt et al.   Nature Reviews Clinical Oncology

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Gain of function of mutant p53: R282W on the peak?

(2016) Y Zhang et al.   Oncogenesis

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53

(2015) S K Alam et al.   CELL DEATH AND DIFFERENTIATION

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

(2015) B S Tan et al.   Cell Death & Disease

Colorectal cancer diagnosis: Pitfalls and opportunities

(2015) Pablo Vega et al.   World Journal of Gastrointestinal Oncology

A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells

(2015) Hongbo Wang et al.   NEOPLASIA

Turning Off AKT: PHLPP as a Drug Target

(2014) Alexandra C. Newton et al.   Annual Review of Pharmacology and Toxicology

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

(2014) David A. Fruman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

(2013) Y. Touil et al.   CLINICAL CANCER RESEARCH

Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion

(2013) Yongheng Chen et al.   NUCLEIC ACIDS RESEARCH

Mechanisms of Action of Bcl-2 Family Proteins

(2013) A. Shamas-Din et al.   Cold Spring Harbor Perspectives in Biology

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53

(2010) Perry Stambolsky et al.   CANCER CELL

Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families Withp53Germline Mutations

(2009) Kelly D. Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Pyroptosis: host cell death and inflammation

(2009) Tessa Bergsbaken et al.   NATURE REVIEWS MICROBIOLOGY

Resistance to chemotherapy: new treatments and novel insights into an old problem

(2008) S Raguz et al.   BRITISH JOURNAL OF CANCER